MRD Testing in GU Cancers: Assessing Test Sensitivity Across Disease States скачать в хорошем качестве

MRD Testing in GU Cancers: Assessing Test Sensitivity Across Disease States

As part of the Oncology Decoded podcast, Benjamin Garmezy, MD, associate director of genitourinary research and executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and a medical oncologist at SCRI Oncology Partners specializing in genitourinary cancers, spoke with various experts at the 2025 World Conference on Genitourinary Cancers (World GU) in Nashville, TN. In this discussion, Garmezy spoke with Benjamin Maughan, MD, PharmD, associate professor in the Division of Medical Oncology at Huntsman Cancer Institute, specializing in genitourinary malignancies, about the role of minimal residual disease (MRD) testing in genitourinary cancers. Maughan noted that for prostate cancer, MRD testing is complex because clinicians already have an "incredibly, exquisitely sensitive" tool: the prostate-specific antigen (PSA) test. He emphasized that while PSA is not perfect, it serves a similar purpose as MRD tests used in other cancers. He suggested that MRD testing might have more utility later in the disease course for prostate cancer. For kidney cancer, Maughan identified KIM-1 as the most promising MRD marker. He highlighted that KIM-1 is a proteomic-based test, which gives it a significant advantage over genomic-based MRD technologies that often have sensitivity issues in kidney cancer. He added that prospective data sets have been retrospectively analyzed and consistently show promising results for KIM-1. The conversation underscores the importance of utilizing different approaches to MRD testing based on the specific type of GU cancer. For more content, including the Oncology Decoded podcast, visit us at www.cancernetwork.com. #MRDtesting #GenitourinaryCancer #GUOncology #ProstateCancer #KidneyCancer #CancerResearch #ClinicalOncology #Biomarkers #PatientCare #Immunotherapy Don't forget to check us out on: YouTube:    / @cancernetwork   X/Twitter: https://x.com/cancernetwrk?lang=en LinkedIn: https://www.linkedin.com/company/canc... Facebook:   / cancer-network-100059801696024   Instagram:   / cancernetwrk